Drug Overview
DCVAC/PCa (SOTIO) is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed dendritic cells cause activation of T cells, which can then recognize and destroy prostate cancer tumor cells.
DCVAC/PCa (SOTIO) is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed dendritic cells cause activation of T cells, which can then recognize and destroy prostate cancer tumor cells.
Table of Contents
Product ProfilesDCVAC/PCa: Prostate cancer
List of Figures
Figure 1: DCVAC/PCa for prostate cancer - SWOT analysis
Figure 2: Drug assessment summary of DCVAC/PCa for prostate cancer
Figure 3: Drug assessment summary of DCVAC/PCa for prostate cancer
Figure 4: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: DCVAC/PCa drug profile
Table 2: DCVAC/PCa Phase III trial in prostate cancer
Table 3: DCVAC/PCa Phase I/II data in prostate cancer
Table 4: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
